PRESS-RELEASE filed May 5, 2026 at 07:00 ET
Ocular Therapeutix reported Q1 2026 EPS of -$0.29, beating consensus of -$0.32 by 9.4%, while revenue of $10.8M was below the $12.7M estimate. The beat was driven by lower-than-expected operating expenses, but the net loss widened to -$88.6M from -$64.1M YoY due to increased R&D spending on AXPAXLI trials. The stock will move on the EPS beat and positive SOL-1 data momentum, offset by revenue miss and cash burn concerns.